Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy

Phase 4

Completed

• Conditions: Epilepsy

• Registration Number: NCT00043914
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study includes patients 16 years of age or older with a confident diagnosis of epilepsy who are currently treated with an antiepileptic drug (AED) monotherapy but require a change in therapy due to inadequate seizure control and/or unacceptable side effects.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-01-14
• Study First Submitted: 2002-08-14
• Study First Submitted QC: 2002-08-15
• Study First Posted: 2002-08-16
• Primary Completion: 2003-01-29
• Study Completion: 2003-01-29
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-06
• Last Update Posted: 2017-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Drug levels of lamotrigine.

Secondary Outcome Measures

Name	Time	Method
This study has no secondary outcome measures.